Brian Feild
Celera Corporation
5 Papers
87 Citations
Brian Feild is an academic researcher from Celera Corporation. The author has contributed to research in topics: Proteome & Bottom-up proteomics. The author has an hindex of 5, co-authored 5 publications.
Chat about Author
Papers
Identification and characterization of angiogenesis targets through proteomic profiling of endothelial cells in human cancer tissues
Mehdi Mesri,Charlie Birse,Jenny Heidbrink,Kathy McKinnon,Erin Brand,Candy Bermingham,Brian Feild,William Fitzhugh,Tao He,Steve Ruben,Paul A. Moore +10 more
TL;DR: Proteomic methods allowed us to focus the authors' studies on the discovery of cell surface/secreted proteins, as they represent key antibody therapeutic and biomarker opportunities and led to previously unidentified functional dependency for B7H3 and ATP1B3.
Reproducibility assessment of relative quantitation strategies for LC-MS based proteomics.
TL;DR: The ratio distribution of the common features successfully indicates the reproducibility of each experiment prior to MS/MS peptide sequencing in three different quantitation strategies: decoupled, coupled isotope-coded affinity tag, and coupled stable isotope labeling of amino acids in cell culture experiments.
38
Quantitation of phosphopeptides using affinity chromatography and stable isotope labeling
TL;DR: An improved methodology was published that showed increased selectivity through esterification of amino acid side chain carboxylic groups of enzymatically digested peptides and its application to the analysis of the effects of serum starvation on in vitro cultured human lung cells is presented.
37
Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer
Sudeepta Aggarwal,Tao He,William Fitzhugh,Kim Rosenthal,Brian Feild,Jenny Heidbrink,Deborah Mesmer,Steven M. Ruben,Paul A. Moore +8 more
TL;DR: Using a MS based proteomics approach, expression of CD70 is associated with cisplatin resistance in ovarian cancer cell lines and follow-up examination of these tumor cell line findings in clinical tumor specimens is warranted.
32
Reference map for liquid chromatography-mass spectrometry-based quantitative proteomics.
Yeoun Jin Kim,Brian Feild,William Fitzhugh,Jenny Heidbrink,James W. Duff,Jeremy Heil,Steven M. Ruben,Tao He +7 more
TL;DR: In this article, a reference map for peptide identifications was built by collecting cysteine-containing peptides from T47D cells and then fractionating them using strong cationic exchange chromatography (SCX).
15